Delving into the Latest Updates on Epinastine Hydrochloride with Synapse

Primary objective: To evaluate the effectiveness of 0.05% epinastine hydrochloride eye drops in the treatment of allergic conjunctivitis, using emedastine fumarate eye drops as a control. Secondary objective: To evaluate the safety of 0.05% epinastine hydrochloride eye drops in the treatment of allergic conjunctivitis.

Start Date22 May 2023

Sponsor / Collaborator

Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.

NCT06212973 / CompletedPhase 3

A Phase 3, Multicenter, Randomized, Double-masked, Active Controlled Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops 0.05% in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients

The goal of this multicenter, randomized, double-blind, active control, non-inferiority clinical trial is to evaluate the efficacy of epinastine hydrochloride eye drops for the treatment of seasonal allergic conjunctivitis using azelastine hydrochloride eye drops as a positive control in Chinese patients. The main question it aims to answer are:
• Is the efficacy for of epinastine hydrochloride eye drops for the treatment of seasonal allergic conjunctivitis non-inferior to azelastine hydrochloride eye drops?Participants will be randomly assigned to the test group or control group in a 1:1 ratio. The test group was treated with epinastine hydrochloride eye drops + azelastine hydrochloride simulating eye drops, and the control group was treated with azelastine hydrochloride eye drops + epinastine hydrochloride simulating eye drops, which were used twice a day for 14 consecutive days.

Start Date13 Mar 2023

Sponsor / Collaborator

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

100 Clinical Results associated with Epinastine Hydrochloride

Login to view more data

100 Translational Medicine associated with Epinastine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Epinastine Hydrochloride

Login to view more data

209

Literatures (Medical) associated with Epinastine Hydrochloride

01 Aug 2024·Hospital Pharmacy

Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan

Article

Author: Kashiwabara, Masami ; Egawa, Kei ; Nakagawa, Naoto ; Sasaki, Ayaka

Objectives: Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are commonly used for its treatment; however, it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese Kampo shoseiryuto (which was traditionally prescribed to treat PAR in Japan) remains poorly understood. In this study, we aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer’s perspective. Methods: The most cost- and clinically effective SGAs were determined from a list of 6 SGAs (bepotastine, 10 mg; cetirizine, 10 mg; ebastine, 10 mg; epinastine, 20 mg; loratadine, 10 mg; and olopatadine, 5 mg) together with shoseiryuto, using the overall improvement rate through a model-based analysis. The time horizon was 28 days. Costs were determined based on the Medical Fee Index in 2020. Deterministic and probabilistic sensitivity analyses were conducted to address the uncertainty of the base-case results. Results: Overall, bepotastine (10 mg) and ebastine (10 mg) were cost-effective. Shoseiryuto was less cost-effective than ebastine (10 mg) (dominated). Ebastine (10 mg) was the most cost-effective option based on deterministic and probabilistic sensitivity analyses. Conclusions: Ebastine (10 mg) was the most cost-effective treatment strategy for PAR among the agents evaluated in this study. This insight could aid in establishing an appropriate formulary for treating PAR in hospitals and communities.

01 Jun 2024·Die Pharmazie

Anti-edematous effects of epinastine, cetirizine and its enantiomers in λ-carrageenan-induced edema in rat hind paw.

Article

Author: Hori, S ; Ozawa, M ; Sakamoto, Y ; Iketani, O ; Enoki, Y ; Matsumoto, K ; Kizu, J ; Taguchi, K ; Chuang, V T G ; Hara, R

Urticaria is induced by the histamine released from mast cells which develops wheals (edema) as a visual feature. In clinical practice, second-generation histamine H₁ -receptor blockers are routinely used as the first-line symptomatic treatment for urticaria. Nevertheless, not much research has directly examined the second-generation histamine H₁-receptor blockers' ability to reduce edema. In this study, we directly evaluated the anti-edematous activities of three second-generation histamine H₁-receptor blockers available in the market (epinastine hydrochloride, cetirizine hydrochloride, and levocetirizine hydrochloride) using a λ-carrageenan-induced footpad edema model. One hour before the induction of edema with 1% λ -carrageenan injection, all second-generation histamine H₁ -receptor blockers (5, 10, 50 and 100 mg/kg) were subcutaneously administered to rats. At 0.5 and 3 hours after λ -carrageenan administration, the edema volume was evaluated using a Plethysmometer. Epinastine hydrochloride significantly suppressed the edema growth in a dose-dependent manner. Cetirizine hydrochloride showed a slight anti-edematous effect, while levocetirizine significantly inhibited the development of edema in a dose-dependent manner. On the other hand, dextrocetirizine did not prevent edema from growing. In summary, second-generation histamine H₁ -receptor blockers, at least those examined in this study, may be able to reduce the clinical symptoms of urticaria associated with edema. Levocetirizine hydrochloride is also anticipated to have stronger anti-edematous effects than cetirizine hydrochloride because levocetirizine is responsible for cetirizine's anti-edematous activity.

30 Apr 2024·Analytical Chemistry

Microliquid/Liquid Interfacial Sensors: Biomimetic Investigation of Transmembrane Mechanisms and Real-Time Determinations of Clemastine, Cyproheptadine, Epinastine, Cetirizine, and Desloratadine

Article

Author: You, Yongtao ; Liu, Cheng ; Bai, Silan ; Wang, Lishi ; Xu, Zhidan

Antihistamines relieve allergic symptoms by inhibiting the action of histamine. Further understanding of antihistamine transmembrane mechanisms and optimizing the selectivity and real-time monitoring capabilities of drug sensors is necessary. In this study, a micrometer liquid/liquid (L/L) interfacial sensor has served as a biomimetic membrane to investigate the mechanism of interfacial transfer of five antihistamines, i.e., clemastine (CLE), cyproheptadine (CYP), epinastine (EPI), desloratadine (DSL), and cetirizine (CET), and realize the real-time determinations. Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) techniques have been used to uncover the electrochemical transfer behavior of the five antihistamines at the L/L interface. Additionally, finite element simulations (FEMs) have been employed to reveal the thermodynamics and kinetics of the process. Visualization of antihistamine partitioning in two phases at different pH values can be realized by ion partition diagrams (IPDs). The IPDs also reveal the transfer mechanism at the L/L interface and provide effective lipophilicity at different pH values. Real-time determinations of these antihistamines have been achieved through potentiostatic chronoamperometry (I-t), exhibiting good selectivity with the addition of nine common organic or inorganic compounds in living organisms and revealing the potential for in vivo pharmacokinetics. Besides providing a satisfactory surrogate for studying the transmembrane mechanism of antihistamines, this work also sheds light on micro- and nano L/L interfacial sensors for in vivo analysis of pharmacokinetics at a single-cell or single-organelle level.

100 Deals associated with Epinastine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01713	Epinastine Hydrochloride	R06AX24 S01GX10	DB00751

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Allergic	JP	Santen Pharmaceutical Co., Ltd.	20 Sep 2013
Psoriasis	CN	Nippon Boehringer Ingelheim Co., Ltd.	16 Jun 2000
Asthma	JP	Nippon Boehringer Ingelheim Co., Ltd.	01 Apr 1994
Eczema	JP	Nippon Boehringer Ingelheim Co., Ltd.	01 Apr 1994
Prurigo	JP	Nippon Boehringer Ingelheim Co., Ltd.	01 Apr 1994
Pruritus	JP	Nippon Boehringer Ingelheim Co., Ltd.	01 Apr 1994
Rhinitis, Allergic	JP	Nippon Boehringer Ingelheim Co., Ltd.	01 Apr 1994
Urticaria	JP	Nippon Boehringer Ingelheim Co., Ltd.	01 Apr 1994

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis, Allergic	Phase 3	CN	Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.	22 May 2023
Seasonal allergic conjunctivitis	Phase 3	CN	Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	10 Mar 2023
Rhinitis, Allergic, Seasonal	Phase 1	-	Merck Sharp & Dohme Corp.	18 Dec 2007
Dermatitis, Atopic	Phase 1	-	Boehringer Ingelheim GmbH	01 Jun 2001
Rhinitis, Allergic, Perennial	Preclinical	-	Boehringer Ingelheim GmbH	01 May 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01363713 (CTgov)	Phase 3	Conjunctivitis, Allergic	130	DE-114	ekwltulray(tmslvninqu) = hdxfzppdqm knnsmyomfo (uabluipmho, wbodhuzeac - hkytuwbwwr) View more	-	23 Sep 2014
NCT00534794 (CTgov)	Phase 4	Conjunctivitis, Allergic	79	Elestat (Elestat)	gjcnyyfqai(tmgywfhjxa) = ymykoalhuy riguvvugqq (aeqskktmjm, grzqqmwnpc - ugcoccknkm) View more	-	27 May 2009
NCT00534794 (CTgov)	Phase 4	Conjunctivitis, Allergic	79	Pataday (Pataday)	gjcnyyfqai(tmgywfhjxa) = wjstyohdnk riguvvugqq (aeqskktmjm, gdzlvlrwni - uzifmckenc) View more	-	27 May 2009
ARVO2003	Not Applicable	Conjunctivitis, Allergic	14	Epinastine hydrochloride 0.05%	(iojuxulzgq) = No adverse events nor any clinically relevant changes in visual acuity, biomicroscopy, ophthalmoscopy, vital signs, physical examination, or laboratory parameters were observed during the study zqaggzlsvy (vpfuonsclr )	Positive	01 May 2003